Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer

April 29th 2024

The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.

Monitoring and AE Management Strategies with Fruquintinib in CRC

April 25th 2024

Margot O'Neill, PA-C, MHS, and Michael Leung, PharmD, discuss the monitoring and adverse effect management strategies for patients with colorectal cancer who receive fruquintinib.

FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

April 25th 2024

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.

FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer

April 25th 2024

CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.

FDA Approves Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs

April 23rd 2024

The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR–positive GEP-NETs.

Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer

April 23rd 2024

Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.

First-Line Pembrolizumab Plus Chemo Wins Canadian Approval for HER2– Advanced Gastric/GEJ Adenocarcinoma

April 19th 2024

Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer.

Durvalumab Plus Chemo Sustains 3-Year OS Benefit in Advanced Biliary Tract Cancer

April 16th 2024

Durvalumab plus chemotherapy produced superior 3-year survival outcomes vs chemotherapy alone in advanced biliary tract cancer.

Trajectory of Evolving HCC Treatment Landscape

April 15th 2024

The expert panelists provide their final insights surrounding the future of HCC treatment management.

REGONEXT Study: Driving Second-line HCC Treatment Strategy

April 15th 2024

Dr Morse discusses key takeaways from the REGONEXT study presented at ASCO GI 2024.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

April 11th 2024

John Strickler, MD, presents the case of a 62-year-old woman with rectal cancer, and Arvind N. Dasari, MD, MS, provides clinical insights on his approach to third-line treatment with regorafenib, highlighting dose strategy and patient education.

Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

April 11th 2024

A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.

Dr Overman on Future Research Directions in GI Cancer

April 11th 2024

Michael J. Overman, MD, discusses future research directions in gastrointestinal cancers.

Insider Insights: Unveiling Takeaways from AACR 2024

April 11th 2024

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

CAN-2409 Receives FDA Orphan Drug Designation in Pancreatic Cancer

April 11th 2024

CAN-2409 has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.

Dr Sahin on the Design of the Northstar Response Assay in Advanced GI Cancer

April 10th 2024

Ilyas Sahin, MD, discusses the Northstar Response assay and the future of precision oncology in patients with advanced gastrointestinal cancer.

Dr Overman on Nonoperative Cancer Management in GI Malignancies

April 9th 2024

Michael J. Overman, MD, discusses the rationale for utilizing a nonoperative management approach over traditional surgery in gastrointestinal cancers.

CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape

April 8th 2024

Key opinion leaders share their takeaways from the CARES-310 trial and its impact on their treatment approach in HCC management.